Granules India Reports 22% YoY Revenue Growth in Q3FY26
Filing Summary
Granules India Ltd. announced its financial results for Q3FY26, reporting a 22% year-over-year increase in revenue from operations, totaling INR 13,879 million. The company’s EBITDA rose by 34% to INR 3,081 million, while profit before tax (PBT) increased by 32% to INR 2,022 million. Net profit after tax (PAT) grew by 28% to INR 1,502 million. The results reflect strong performance in the Finished Dosages segment across North America and Europe. The company’s net debt stood at INR 10,151 million with a net debt to EBITDA ratio of 0.91x.
Granules India Ltd. has released its financial results for the third quarter of the fiscal year 2026, ending December 31, 2025. The company reported a 22% year-over-year increase in revenue from operations, reaching INR 13,879 million. The EBITDA for the quarter was INR 3,081 million, marking a 34% increase from the previous year. The profit before tax (PBT) stood at INR 2,022 million, a 32% rise year-over-year, while the profit after tax (PAT) was INR 1,502 million, reflecting a 28% increase.
The financial performance of Granules India Ltd. in Q3FY26 highlights significant growth across key financial metrics. The EBITDA margin improved to 22% from 20% in the same quarter last year. The company’s net debt was reported at INR 10,151 million, with a net debt to EBITDA ratio of 0.91x. The return on capital employed (ROCE) post-acquisition of Senn Chemicals AG was 16.8%, compared to 16.4% in the previous year.
Granules India’s operations in Q3FY26 were driven by the performance of its Finished Dosages (FD) segment, which contributed 76% to the revenue from operations. The Active Pharmaceuticals Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) segments each contributed 11%, while Peptides/CDMO accounted for 2% of the revenue. The company’s strategic focus on expanding its presence in North America and Europe has been a key factor in its revenue growth.
The company’s financial results were released in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results reflect Granules India’s ongoing efforts to strengthen its market position through disciplined execution of strategic growth initiatives. The company continues to invest in research and development and expand its global supply footprint.
Granules India Ltd. reported its financial results on January 23, 2026. The company operates with a vertically integrated business model, covering the entire pharmaceutical value chain from APIs to Finished Dosages. The company has a global presence, distributing products to over 300 customers in more than 80 countries. Granules India has 11 manufacturing facilities, with eight located in India, two in the USA, and one in Switzerland.
Granules India Ltd. is a pharmaceutical company focused on manufacturing and distributing a wide range of pharmaceutical products. The company is committed to operational excellence and quality, with a strategic emphasis on expanding its global footprint and enhancing its product offerings. Granules India continues to pursue growth opportunities in regulated and semi-regulated markets worldwide.